Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Adaptimmune initiates Phase I/II metastatic melanoma drug trial
The trial is intended to evaluate the safety, bioactivity and anti-tumor effect of patients’ own T cells that have been genetically modified to express a high affinity T
The trial is intended to evaluate the safety, bioactivity and anti-tumor effect of patients’ own T cells that have been genetically modified to express a high affinity T
ALS-2200 and ALS-2158, currently in preclinical development, are designed to inhibit the replication of the hepatitis C virus by acting on the NS5B polymerase. As part of the
The Phase I trial is expected to assess safety along with the immunological and biological effects of ZIN ATI-001 in patients with melanoma. ZIN ATI-001 employs an adenoviral
Merck’s Label Standardization Project includes evaluating the proposed label content and layout, selecting new packaging design, and obtaining regulatory approval to implement the new packaging design. The Label
The tie up allows Pall to use the services of Avacta and market joint services in North America, and in other regions globally where Avacta is not currently
Following the investment by Quintiles, Kareus plans to submit an investigational new drug (IND) application for KU-046, a first-in-class new chemical entity discovered by Kareus for the treatment
VX-770 is a medicine in development for people with cystic fibrosis who are 6 years or older and have at least one copy of the G551D mutation. The
The new patent entitled, ‘Deep Draw Container Forming Method,’ covers manufacturing technology of VersiDoser and VRx2 drug and biologic delivery systems. Mystic claims its delivery platforms offer preservative
The trial evaluated patients who were divided into three arms: placebo, low dose and high dose EPI-A0001. In the trial, EPI-A0001 improved neurological function as assessed by the
The launch follows the approval from the US Food and Drug Administration for Letrozole 2.5mg Tablets’ abbreviated new drug application (ANDA). Letrozole tablets are bioequivalent to Novartis’ Femara,